Howard N. Hodis, M.D.
Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology; Professor of Medicine and Preventive Medicine; Professor of Molecular Pharmacology and Toxicology; Director, Atherosclerosis Research Unit; Division of Cardiovascular Medicine; Keck School of Medicine; University of Southern California
Benefits and risk of menopausal hormone replacement therapy (MHT) are predominantly determined by timing of initiation relative to menopause and/or age. This presentation will specifically review all-cause mortality and cardiovascular disease (CVD) effects of MHT initiated in proximity and distal to menopause. Additionally, MHT will be presented in clinical perspective and risks discussed relative to benefits.